Handelsavisen
prelaunch
Companies Healthcare RANI.TA
RA
RANI.TA TASE (Tel Aviv) Pharmaceuticals & Medical Research

Rani Zim Shopping Centers Ltd

$468,80
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
3,35 %
Op margin
110,2 %
ROE
8,2 %
Net margin
46,0 %
Debt / equity
2,11
Beta
52w range
Volume
Day range
Prev close
$0,67
Open
$0,68
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

The company maintains a capital structure with a debt-to-equity ratio of 2.11, indicating a significant reliance on debt financing. Liquidity is constrained, as evidenced by a current ratio of 0.8, and the firm holds only 7.5 million ILS in cash and equivalents, which is insufficient to cover its long-term debt of 2.12 billion ILS. This suggests a potential liquidity risk, particularly if short-term obligations exceed available cash flow. Profitability metrics show a return on equity (ROE) of 8.23% and a return on assets (ROA) of 2.43%. These figures are below the industry median for ROE and ROA in the Real Estate Rental, Development & Operations sector, indicating that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. Geographically and segment-wise, the company's revenue is concentrated in Israel, with no disclosed international operations. The business is entirely focused on real estate rental and management, with no diversification into other segments. This concentration increases exposure to local economic and regulatory risks. Looking ahead, the company is projected to maintain a stable revenue trajectory, with no si

Business. Rani Zim Shopping Centers Ltd (RANI.TA) is a real estate company engaged in the rental, development, and operations of shopping centers. The firm is headquartered in Israel and primarily listed on the Tel Aviv Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed.

Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY4 analysts
4 buy0 hold0 sell
Avg 12m price target7,50

Analyst recommendations

4 analysts · consensus Buy
Buy4
Hold0
Sell0
12-month price target
7,50
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
4 analysts · indicative
Ownership
Vanguard Capital Management, LLC
largest disclosed fund holder
Profitability
8,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning RANI.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to RANI.TA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Rani Zim Shopping Centers Ltd (RANI.TA) is a real estate company engaged in the rental, development, and operations of shopping centers. The firm is headquartered in Israel and primarily listed on the Tel Aviv Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed.

    Classification99 %
    SectorHealth Care
    Industry groupPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company maintains a capital structure with a debt-to-equity ratio of 2.11, indicating a significant reliance on debt financing. Liquidity is constrained, as evidenced by a current ratio of 0.8, and the firm holds only 7.5 million ILS in cash and equivalents, which is insufficient to cover its long-term debt of 2.12 billion ILS. This suggests a potential liquidity risk, particularly if short-term obligations exceed available cash flow.

    Profitability metrics show a return on equity (ROE) of 8.23% and a return on assets (ROA) of 2.43%. These figures are below the industry median for ROE and ROA in the Real Estate Rental, Development & Operations sector, indicating that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization.

    Geographically and segment-wise, the company's revenue is concentrated in Israel, with no disclosed international operations. The business is entirely focused on real estate rental and management, with no diversification into other segments. This concentration increases exposure to local economic and regulatory risks.

    Looking ahead, the company is projected to maintain a stable revenue trajectory, with no significant growth expected in the next fiscal year. Historical revenue of 179.15 million ILS reflects a mature business model with limited expansion opportunities. The outlook for operating income and net income is similarly flat, with no material changes anticipated in the near term.

    Risk factors include a medium liquidity risk due to the low cash balance and high debt load, as well as a potential credit risk from the elevated leverage. The firm has a low dilution risk, as shares outstanding remain unchanged between basic and diluted counts. However, the negative net cash position after subtracting total debt raises concerns about the company's ability to meet long-term obligations without refinancing or asset sales.

    Recent filings and transcripts have not disclosed any material events or strategic shifts. The company appears to be operating in a stable but low-growth environment, with no significant capital expenditures or R&D investments reported.

    Key takeaways
    • The company is highly leveraged, with a debt-to-equity ratio of 2.11, which increases financial risk.
    • ROE and ROA are below industry medians, suggesting suboptimal capital and asset utilization.
    • Revenue is concentrated in Israel, with no international diversification, increasing exposure to local economic conditions.
    • Liquidity is constrained, with a current ratio of 0.8 and insufficient cash to cover long-term debt.
    • No significant growth is expected in the near term, with a stable but low-revenue trajectory.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $468,80
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $1.00B
    Net cash
    -$2.11B
    Current ratio
    0.8
    Debt / equity
    2.1
    ROA
    2.4%
    ROE
    8.2%
    Cash conversion
    50.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryPharmaceuticals & Medical Research15,2B node revenueKLAR 23,0%BNTX 21,4%EXEL 15,2%MDGL 6,3%INSM 4,0%VCYT 3,4%MDXG 2,8%AVIR 2,3%Other 21,6%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)RANI 0,0% · rank #70 of 109

    Business relationships

    Business relationships4 disclosed relationships · 2 types · extracted from filings & disclosures
    Partners2
    Subsidiaries2
    EX21:0666a43905c1EX21:0666a43905c1Subsidiarie97%
    EX21:999a94444568EX21:999a94444568Subsidiarie97%Source ↗

    Supply chain

    Vendors → RANI ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSRANIRANIRani Zim Shopping Centers Ltd4 entitiesCelltrion IncOil & Gas Exploration & KRChugai Pharmaceutical UnclassifiedJP
    2 mentions in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    Peer comparison8 peers · vs RANI · multiples and returns
    KL
    KLAR
    KLAR.ST
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    BN
    BNTX
    Biontech SE
    $92,25
    23,3B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    EX
    EXEL
    Exelixis Inc
    $55,06
    14,7B USD
    P/E
    19,5x
    vs self
    Div yield
    vs self
    ROE
    40,4 %
    +144,9 vs self
    MD
    MDGL
    Madrigal Pharmaceuticals Inc
    $482,00
    11,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -47,8 %
    +56,6 vs self
    IN
    INSM
    Insmed Inc
    $107,46
    23,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -160,2 %
    -55,7 vs self
    VC
    VCYT
    Veracyte Inc
    $45,30
    3,6B USD
    P/E
    55,5x
    vs self
    Div yield
    vs self
    ROE
    5,1 %
    +109,5 vs self
    MD
    MDXG
    Mimedx Group Inc
    $4,27
    636,0M USD
    P/E
    11,1x
    vs self
    Div yield
    vs self
    ROE
    18,9 %
    +123,4 vs self
    AV
    AVIR
    Atea Pharmaceuticals Inc
    $4,61
    P/E
    vs self
    Div yield
    vs self
    ROE
    -57,5 %
    +47,0 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 48 %
    EPS
    Consensus EPS
    -0,18
    Predicted surprise
    -0,08
    Beat probability
    48 %
    Analysts
    4
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    revision ratio 0,06 · as of 2026-07-17 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$5,00
    Mean$7,50
    Median$7,00
    High$11,00
    Spot$468,80
    −98.4 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin110,2 %Above P75
    Net Margin46,0 %Above P75
    ROE8,2 %Above median
    D/E2,11Bottom quartile
    Cash Conv0,50Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 8 435 934 sh11 grants9 insiders
    • McKinley KateChief Business Officer · Stock Option (Right to Buy) → Class A Common StockAcquired 805 500 @ $0,88grant · 2026-06-03
    • Imran TalatDirector, Chief Executive Officer · Stock Option (Right to Buy) → Class A Common StockAcquired 3 800 000 @ $0,88grant · 2026-06-03
    • Javadi AlirezaChief Technical Officer · Stock Option (Right to Buy) → Class A Common StockAcquired 805 500 @ $0,88grant · 2026-06-03
    • IMRAN MIR ADirector, 10% owner · Director Stock Option (Right to Buy) → Class A Common StockAcquired 123 600 @ $0,95grant · 2026-05-28
    • Rometty Lisa AnnDirector · Director Stock Option (Right to Buy) → Class A Common StockAcquired 123 600 @ $0,95grant · 2026-05-28
    • Bailey Vasudev JaiprakashDirector · Director Stock Option (Right to Buy) → Class A Common StockAcquired 123 600 @ $0,95grant · 2026-05-28
    • BUTEL JEAN LUCDirector · Director Stock Option (Right to Buy) → Class A Common StockAcquired 123 600 @ $0,95grant · 2026-05-28
    • Bassan AbrahamDirector · Director Stock Option (Right to Buy) → Class A Common StockAcquired 123 600 @ $0,95grant · 2026-05-28
    • Ausiello Dennis ADirector · Director Stock Option (Right to Buy) → Class A Common StockAcquired 123 600 @ $0,95grant · 2026-05-28
    • IMRAN MIR ADirector, 10% owner · Warrant to Purchase Class A Common Stock → Class A Common StockAcquired 2 083 334 @ $0,48purchase · 2025-10-23
    • Bassan AbrahamDirector · Stock Option (Right to Buy) → Class A Common StockAcquired 100 000 @ $2,09grant · 2025-10-23
    • Bailey Vasudev JaiprakashDirector · Stock Option (Right to Buy) → Class A Common StockAcquired 100 000 @ $2,09grant · 2025-10-23

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • Rani Zim Shopping Centers Ltd Market data — financials · 2026-05-29

    Ownership & reference

    Top holders

    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$7M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$1M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$0M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

    Leadership

    • Mir A ImranExecutive Chairman of the Board

    Insider activity

    Net selling1 buys · 2 sellsnet -$14,5M2 insiders · last 365d
    • IMRAN MIR ADirector, 10% owner · Class A Common StockBought 2 083 334 @ $0,60$1,3M · 2025-10-23
    • South Cone Investments Limited Partnership10% owner · Class A Common StockSold 4 000 000 @ $2,77$11,1M · 2025-10-21
    • South Cone Investments Limited Partnership10% owner · Class A Common StockSold 1 923 000 @ $2,41$4,6M · 2025-10-20

    Short positioning

    8.8Mshares short-2.6% vs prior
    11.29days to cover
    37.3%short of daily vol
    511fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    RANI.TACanonical
    TASE (Tel Aviv) · USD

    Intel & risk

    PredictorBeat prob48 %Surprise-0,08Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    RANI068270.K4519.TEX21:066EX21:999Pharmaceutical
    This companySectorPartnersSubsidiaries

    Evidence & claims

    From filings & derived data
    • Debt-to-equity (FY 2025-12-31): 0.52xDerived (calculated)
    • Net margin (FY 2025-12-31): -1,817.1%Derived (calculated)
    • Return on equity (FY 2025-12-31): -89.9%Derived (calculated)
    • Return on assets (FY 2025-12-31): -50.6%Derived (calculated)
    • Current ratio (FY 2025-12-31): 4.21xDerived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): -67.2%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 394.9%Derived (calculated)
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -100.0%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 47.3%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 28.1%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): -24.3%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 58.9%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 1,557.1%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 60.0%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -48.4%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 57.1%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 57.1%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): 1.1%Derived (calculated)
    • Net income (annual): USD -29.67MSEC XBRL filing
    • Long-term debt (annual): USD 0SEC XBRL filing
    • Total assets (annual): USD 58.62MSEC XBRL filing
    • Operating cash flow (annual): USD -18.71MSEC XBRL filing
    • Current liabilities (annual): USD 12.67MSEC XBRL filing
    • Shareholders' equity (annual): USD 33.01MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-29 22:34 UTCEVENTHa Price Listing RANI remains DEFICIENT (NASDAQ) — cure period. closed below $1.00 for 44 consecutive trading days (last close $0.7913). cure deadline 2027-01-17 (172 days remaining).
    2026-07-12 21:55 UTCEVENTHa Price Listing RANI has closed below $1.00 for 32 consecutive available trading days — Nasdaq/NYSE minimum-bid deficiency threshold (30d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-03 00:00 UTCINSIDER3 insider transactions — 2026-06 3 derivative
    2026-06-03INSIDERJavadi Alireza acquired 805.5k sh Stock Option (Right to Buy) — Chief Technical Officer
    2026-06-03INSIDERImran Talat acquired 3.80M sh Stock Option (Right to Buy) — Director, Chief Executive Officer
    2026-06-03INSIDERMcKinley Kate acquired 805.5k sh Stock Option (Right to Buy) — Chief Business Officer
    2026-05-29FILING8-K filing →
    2026-05-28 00:00 UTCINSIDER6 insider transactions — 2026-05 6 derivative
    2026-05-28INSIDERBUTEL JEAN LUC acquired 123.6k sh Director Stock Option (Right to Buy) — Director
    2026-05-28INSIDERBailey Vasudev Jaiprakash acquired 123.6k sh Director Stock Option (Right to Buy) — Director
    2026-05-28INSIDERAusiello Dennis A acquired 123.6k sh Director Stock Option (Right to Buy) — Director
    2026-05-28INSIDERBassan Abraham acquired 123.6k sh Director Stock Option (Right to Buy) — Director
    2026-05-28INSIDERRometty Lisa Ann acquired 123.6k sh Director Stock Option (Right to Buy) — Director
    2026-05-28INSIDERIMRAN MIR A acquired 123.6k sh Director Stock Option (Right to Buy) — Director, 10% owner
    2026-05-27FILING8-K filing →
    2026-05-27FILING424B5 filing →
    2026-05-15FILING10-Q filing →
    2026-05-15FILING8-K filing →
    2026-04-16FILINGDEF 14A filing →
    2026-03-26FILING10-K filing →
    2026-03-26FILING8-K filing →
    2026-01-02FILING8-K filing →
    2025-12-03FILING424B5 filing →
    2025-11-06FILING10-Q filing →
    2025-11-06FILING8-K filing →
    2025-10-23 00:00 UTCINSIDER6 insider transactions — 2025-10 · net sell $14.5M 3 derivative
    2025-10-23INSIDERIMRAN MIR A bought 2.08M sh Class A Common Stock — Director, 10% owner ~$1.26M
    2025-10-23INSIDERBassan Abraham acquired 100.0k sh Stock Option (Right to Buy) — Director
    2025-10-23INSIDERBailey Vasudev Jaiprakash acquired 100.0k sh Stock Option (Right to Buy) — Director
    2025-10-23INSIDERIMRAN MIR A acquired 2.08M sh Warrant to Purchase Class A Common Stock — Director, 10% owner
    2025-10-21INSIDERSouth Cone Investments Limited Partnership sold 4.00M sh Class A Common Stock — 10% owner ~$11.07M
    2025-10-20INSIDERSouth Cone Investments Limited Partnership sold 1.92M sh Class A Common Stock — 10% owner ~$4.64M
    2025-08-01 00:00 UTCINSIDER1 insider transaction — 2025-08 1 derivative
    2025-08-01INSIDERMcKinley Kate acquired 120.0k sh Employee Stock Option (Right to Buy) — Chief Business Officer
    2025-05-28 00:00 UTCINSIDER8 insider transactions — 2025-05 8 derivative
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage